[go: up one dir, main page]

MA39725B1 - Compositions pharmaceutiques de composés thérapeutiquement actifs - Google Patents

Compositions pharmaceutiques de composés thérapeutiquement actifs

Info

Publication number
MA39725B1
MA39725B1 MA39725A MA39725A MA39725B1 MA 39725 B1 MA39725 B1 MA 39725B1 MA 39725 A MA39725 A MA 39725A MA 39725 A MA39725 A MA 39725A MA 39725 B1 MA39725 B1 MA 39725B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
active compounds
therapeutically active
treating cancer
compounds
Prior art date
Application number
MA39725A
Other languages
English (en)
Inventor
Chong-Hui Gu
Original Assignee
Les Laboratoires Servier Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier Sas filed Critical Les Laboratoires Servier Sas
Publication of MA39725B1 publication Critical patent/MA39725B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ecology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des composés et des compositions pharmaceutiques utiles pour traiter le cancer, et des méthodes de traitement du cancer comprenant l'administration, à un patient en ayant besoin, d'un composé ou d'une composition pharmaceutique décrit(e) dans la description.
MA39725A 2014-03-14 2015-03-13 Compositions pharmaceutiques de composés thérapeutiquement actifs MA39725B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461953480P 2014-03-14 2014-03-14
PCT/US2015/020346 WO2015138837A1 (fr) 2014-03-14 2015-03-13 Compositions pharmaceutiques de composés thérapeutiquement actifs

Publications (1)

Publication Number Publication Date
MA39725B1 true MA39725B1 (fr) 2021-09-30

Family

ID=54072439

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39725A MA39725B1 (fr) 2014-03-14 2015-03-13 Compositions pharmaceutiques de composés thérapeutiquement actifs

Country Status (28)

Country Link
US (1) US20170007661A1 (fr)
EP (1) EP3116491B1 (fr)
JP (3) JP6524119B2 (fr)
KR (1) KR102458157B1 (fr)
CN (2) CN106163507B (fr)
AU (2) AU2015229212B2 (fr)
BR (2) BR122023021436A2 (fr)
CA (1) CA2942070A1 (fr)
CY (1) CY1125205T1 (fr)
DK (1) DK3116491T3 (fr)
EA (2) EA202090098A1 (fr)
ES (1) ES2881858T3 (fr)
HR (1) HRP20211233T1 (fr)
HU (1) HUE055209T2 (fr)
IL (1) IL247721B (fr)
LT (1) LT3116491T (fr)
MA (1) MA39725B1 (fr)
MX (2) MX2016011865A (fr)
NZ (1) NZ723860A (fr)
PH (1) PH12016501788B1 (fr)
PL (1) PL3116491T3 (fr)
PT (1) PT3116491T (fr)
RS (1) RS62178B1 (fr)
SI (1) SI3116491T1 (fr)
SM (1) SMT202100444T1 (fr)
UA (2) UA129317C2 (fr)
WO (1) WO2015138837A1 (fr)
ZA (1) ZA201606134B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
FI3362065T3 (fi) 2015-10-15 2024-06-19 Servier Lab Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
HRP20211790T1 (hr) 2015-10-15 2022-03-04 Les Laboratoires Servier Kombinirana terapija za liječenje maligniteta
KR20180086255A (ko) 2015-12-04 2018-07-30 아지오스 파마슈티컬스 아이엔씨. 악성종양의 치료 방법
EP3402571A4 (fr) * 2016-01-15 2019-08-28 The J. David Gladstone Institutes Méthodes de traitement de maladies par la régulation métabolique de la différenciation des lymphocytes t
WO2017146794A1 (fr) 2016-02-26 2017-08-31 Celgene Corporation Inhibiteurs d'idh2 pour le traitement de tumeurs solides et malignes hématologiques
WO2018085486A1 (fr) 2016-11-02 2018-05-11 University Of Cincinnati Compositions et méthodes de traitement de patients souffrant de gliome ou de leucémie
CN110475557B (zh) * 2017-01-20 2023-06-20 星座制药公司 固体分散体
FI3686191T3 (fi) 2017-09-22 2023-01-31 Kiteinen sulfamidiyhdiste
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
MX2021000068A (es) * 2018-07-06 2021-03-25 Agios Pharmaceuticals Inc Formas y composiciones farmaceuticas de ivosidenib.
US20210069113A1 (en) * 2019-09-11 2021-03-11 Modavar Pharmaceuticals LLC Solid unit dosage form for dose individualized drug delivery
AR123228A1 (es) 2020-08-12 2022-11-09 Servier Pharmaceuticals Llc Formas en estado sólido de un compuesto orgánico
JP2023544998A (ja) * 2020-10-02 2023-10-26 ロンザ・ベンド・インコーポレーテッド 塩基性薬物の噴霧乾燥における加工助剤としての酢酸
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343548B2 (en) * 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
MX2009006806A (es) * 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
WO2010059239A2 (fr) * 2008-11-21 2010-05-27 Millennium Pharmaceuticals, Inc Sel de lactate du (4-isopropoxyphényl)-amide de l’acide 4-(6-méthoxy-7-(3-pipéridin-1-yl-propoxy)quinazolin-4-yl]pipérazine-1-carboxylique et les compositions pharmaceutiques l’incluant dans le traitement du cancer et d'autres pathologies ou troubles
CN108524505A (zh) * 2009-03-13 2018-09-14 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
AU2010259002B2 (en) * 2009-06-08 2014-03-20 Nantbio, Inc. Triazine derivatives and their therapeutical applications
US8652534B2 (en) * 2009-10-14 2014-02-18 Berry Pharmaceuticals, LLC Compositions and methods for treatment of mammalian skin
WO2012054698A1 (fr) * 2010-10-21 2012-04-26 Biomarin Pharmaceutical Inc. Sel tosylate de la (8s,9r)-5-fluoro-8-(4-fluorophényl)-9-(1-méthyl-1h- 1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phtalazin-3(7h)-one cristallin
CN102827170A (zh) * 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
DK2800743T3 (en) * 2012-01-06 2018-06-14 Agios Pharmaceuticals Inc THERAPEUTIC ACTIVE RELATIONS AND PROCEDURES FOR USE THEREOF
US9474779B2 (en) * 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014015422A1 (fr) * 2012-07-27 2014-01-30 Ontario Institute For Cancer Research Nanoparticules à base de cellulose pour administration de médicament
WO2015127173A1 (fr) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Composés thérapeutiquement actifs et leurs procédés d'utilisation

Also Published As

Publication number Publication date
HUE055209T2 (hu) 2021-11-29
CN106163507A (zh) 2016-11-23
PH12016501788B1 (en) 2021-12-15
BR112016021012A2 (pt) 2018-08-07
CA2942070A1 (fr) 2015-09-17
LT3116491T (lt) 2021-08-10
MX2021001739A (es) 2021-04-19
BR122023021440A2 (pt) 2023-12-12
BR122023021436A2 (pt) 2023-12-12
NZ723860A (en) 2023-04-28
EA202090098A1 (ru) 2020-11-30
JP2017508804A (ja) 2017-03-30
IL247721B (en) 2020-04-30
EP3116491A4 (fr) 2017-11-15
JP2021088605A (ja) 2021-06-10
UA122962C2 (uk) 2021-01-27
UA129317C2 (uk) 2025-03-19
BR112016021012B1 (pt) 2024-01-23
EA034366B1 (ru) 2020-01-31
AU2019232825A1 (en) 2019-10-10
HRP20211233T1 (hr) 2021-10-29
EP3116491A1 (fr) 2017-01-18
PH12016501788A1 (en) 2016-12-19
RS62178B1 (sr) 2021-08-31
JP2019163278A (ja) 2019-09-26
EP3116491B1 (fr) 2021-05-05
JP6524119B2 (ja) 2019-06-05
SMT202100444T1 (it) 2021-09-14
AU2019232825B2 (en) 2021-08-05
KR102458157B1 (ko) 2022-10-24
SI3116491T1 (sl) 2021-12-31
CY1125205T1 (el) 2023-03-24
MX2016011865A (es) 2017-04-13
KR20160124907A (ko) 2016-10-28
CN106163507B (zh) 2020-06-26
WO2015138837A1 (fr) 2015-09-17
IL247721A0 (en) 2016-11-30
AU2015229212A1 (en) 2016-09-22
DK3116491T3 (da) 2021-08-09
ZA201606134B (en) 2024-01-31
CN112206232A (zh) 2021-01-12
PL3116491T3 (pl) 2022-02-07
AU2015229212B2 (en) 2019-06-20
ES2881858T3 (es) 2021-11-30
EA201691844A1 (ru) 2016-12-30
US20170007661A1 (en) 2017-01-12
PT3116491T (pt) 2021-08-10

Similar Documents

Publication Publication Date Title
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
EP2868667A4 (fr) Agent thérapeutique à base d'anticorps anti-bmp9 en tant que principe actif, pour le traitement de l'anémie, notamment une anémie rénale et une anémie liée à un cancer
MA50240A (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
EP3356522A4 (fr) Compositions contenant un exosome chargé d'une protéine, et procédés de préparation et d'administration correspondants
EA201491299A1 (ru) Карбаматные соединения, их получение и применение
EA201790174A1 (ru) Антипролиферативные соединения и способы их применения
MA40290A1 (fr) Agents immunorégulateurs
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MA39443A1 (fr) Nouvelle formulation de méloxicam
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
EP3417853A4 (fr) Composition pharmaceutique pour le traitement d'un cancer, contenant un composé polyphénol utilisé comme principe actif
MA43294A1 (fr) Sels et promédicaments de 1-méthyl -d-tryptophane
MA42301B1 (fr) Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MX381526B (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal crónica.
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA46778A1 (fr) Composition intranasale comprenant de la bétahistine